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Abstract
BACKGROUND: to study the effect of lipid depressing drugs on
18FDG myocardial concentration. The changes of 18FDG uptake
in myocardium, brain and skeletal muscle of rats were compared
as influenced by acipimox, tyloxapol and glucose with insulin.
MATERIAL AND METHODS: 5.55 MBq of 18FDG were adminis-
tered to Wistar rats. Control rats were killed 15, 30, 45 and 60
minutes following intravenous injection and the radioactivity con-
centration (cpm/g of tissue) in relation to injected cpm was deter-
mined in a well crystal adjusted to 511 KeV in order to check the
time of maximal 18FDG tissue uptake. The radioactivity in myo-
cardium, skeletal muscle and brain in intact animals was com-
pared with that of rats treated with tyloxapol (tritton WR 1339,
125 mg intravenously immediately before 18FDG injection), acipi-
mox (nicotinic acid derivative, 25 mg by stomach cannula
15 minutes before 18FDG), or glucose with insulin (intravenous
18F-fluorodeoxyglucose accumulation
in the heart, brain and skeletal muscle
of rats; the influence of time after
injection, depressed lipid metabolism
and glucose-insulin
injection of 0.04 g and 0.04 UI immediately before 18FDG). The
animals were killed 45 minutes following 18FDG injection.
RESULTS: Tyloxapol and acipimox significantly elevated myo-
cardial 18FDG concentration (tyloxapol +37% and acipimox
+48%), but the increase in 18FDG concentration after glucose
and insulin was slight and insignificant. The changes in skeletal
muscle after lipid depressing agents were quite contrasting; the
decrease in 18FDG concentration was 74% after tyloxapol and
44% following acipimox administration. The accumulation of
18FDG in brain was not influenced markedly by the drugs used
or by glucose with insulin.
CONCLUSION: The highest 18FDG uptake in myocardium could
be achieved by depressing the lipid metabolism and not by
administration of glucose with insulin only. A marked increase
in glucose accumulation in myocardium is not possible without
previous shift from the utilisation of fatty acids. This finding is
fully in agreement with present knowledge about energetic
metabolism of myocardium.
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Introduction
Free fatty acids (FFA) represent the main energetic fuel for nor-
moxic myocardium [1], but glucose is beginning to be the main
source of energetic metabolism, in the case of oxygen lack, de-
manding anaerobic metabolism together with stimulation of glu-
cose uptake and gluconeogenesis [2].
Fluorodeoxyglucose labelled by positron emitter 18F (18FDG)
has been widely used for scintigraphic imaging of normal and
viable myocardium because the uptake of 18FDG in myocytes is
similar to endogenic glucose [3].
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It seems to be essential to increase myocardial uptake of 18FDG
and to elevate myocardial concentration in order to achieve better
PET scintigrams. There are two clinically used possibilities: either to
increase the affinity for glucose by insulin or to depress the lipid me-
tabolism of the myocardium. The first technique has some limita-
tions, in particular in diabetic patients, and therefore an insulin-glu-
cose clamp is practised. However preceding saturation of myocar-
dium by glucose before 18FDG application seems to be rather con-
tradictory. The second possibility is to decrease pharmaceutically
the uptake of FFA and myocardial lipid turnover and to provoke
a shift of predominantly lipid utilisation to the glucose metabolism.
Most of the published data describing the influence of both
techniques on 18FDG uptake in the human heart have been gained
by PET scintigraphy. However this procedure cannot be accurate
for determination of 18FDG-tissue concentration and therefore ex-
act results could be obtained in animal experiments only.
The aim of our study was to determine the influence of antil-
ipemic agents and glucose with insulin on 18FDG concentration in
the heart of rat at a time of maximal uptake after intravenous injec-
tion. Prior to this determination it was necessary to check the time
of maximal tissue uptake following intravenous application of
18FDG. The differences in myocardial 18FDG uptake could be more
evident in comparison with other tissues, in particular with brain
and skeletal muscle.
Material and methods
The experiments were carried out on Wistar rats of 180 g weight
(175200 g). 5.55 MBq of 18FDG produced by a cyclotron unit at
the Nuclear Physics Institute was injected intravenously. Groups
of control rats, consisting of 5 animals, were killed 15, 30, 45 and
60 minutes following 18FDG injection. All important organs or sam-
ples of tissues were weighed and measured for radioactivity. The
radioactivity concentration (cpm/g of tissue) in relation to total in-
jected cpm was determined in a well detector adjusted to 511
KeV in order to define optimal time of maximal 18FDG tissue accu-
mulation after its intravenous injection. Tissue radioactivity con-
centration in myocardium, brain and skeletal muscle of control
animals was compared with that of another groups of rats (con-
sisting of at least 5 animals) treated by drugs with expected influ-
ence on 18FDG accumulation in the myocardium.
For lipid metabolism depressing, the following drugs were used:
a) tyloxapol (triton WR 1339), experimentally used for its blocking of
superficial membranes, inhibiting lipoprotein transport into the cells
and blocking hormone-sensitive lipase (intravenous injection of 125
mg immediately preceding 18FDG injection), b) acipimox (Olbetamfi,
Pharm&Upjohn S.p.a., Italy), dissolved in water, 25 mg by stomach
cannula 15 minutes prior to 18FDG. Another group of animals was
treated by intravenous injection of 0.04 g of glucose and 0.04 UI of
insulin immediately before 18FDG application.
All rats given drugs were killed 45 minutes after 18FDG injec-
tion, i.e. at the time of maximal 18FDG tissue accumulation.
Results
The uptake of 18FDG in the heart, brain, kidney, liver, spleen,
lungs and skeletal muscle with blood radioactivity related to the
period after intravenous injection shows that maximal radioactivi-
Table 1. The 18FDG concentration (mean – STD), expressed in %
(cpm/g of tissue), related to the total injected cpm
15 min. 30 min. 45 min. 60 min.
blood 0.78 – 0.07 0.60 ± 0.07 0.26 – 0.06 0.15 – 0.01
myocardium 6.13 – 0.30 6.37 – 0.81 7.20 – 1.38 5.39 – 1.29
lungs 0.92 – 0.05 1.08 – 0.13 0.84 – 0.14 0.46 –  0.12
spleen 0.82 – 0.09 1.12 – 0.14 0.86 – 0.09 0.73 – 0.10
kidney 1.59 – 0.14 1.24 – 0.21 0.66 – 0.11 0.62 – 0.05
skeletal muscle 0.30 – 0.04 0.51 – 0.05 0.87 – 0.22 0.35 – 0.13
brain 2.72 – 0.32 2.16 – 0.14 2.74 – 0.46 1.58 – 0.19
liver 0.88 – 0.07 0.58 – 0.05 0.28 – 0.01 0.16 – 0.01
ty concentration in myocardium, brain and muscle was achieved
in 45 minutes (Tab. 1). Therefore this time period from 18FDG in-
jection to the killing of animals was used in all groups of rats treat-
ed by the studied drugs.
There are great differences in 18FDG accumulation between tis-
sues. The highest radioactivity concentration in control rats was in
the heart, nearly three times higher when compared with the brain
and more than seven times higher than in other organs. The con-
centration of 18FDG in myocardium was 8 times that in spleen, 11
times in kidney and 16 times in liver. Blood background gradually
decreased during the first hour. Therefore we compared the effect
of the tested drugs on 18FDG uptake in myocardium, brain, and
also in skeletal muscle having another energetic metabolism.
Both tyloxapol and, even more, acipimox significantly increased
myocardial uptake of 18FDG; its concentration was, in comparison with
control group of animals, 37% and 47% higher, respectively. The in-
crease after glucose with insulin was slight and insignificant (Fig. 1)
The influence of the tested drugs on the accumulation of 18FDG
in skeletal muscle was quite opposite to that in the myocardium.
Whereas glucose and insulin increased slightly the concentration
of 18FDG, acipimox and, even more, tyloxapol markedly decreased
tissue uptake of 18FDG (Fig. 2).
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Figure 1. Accumulation of 18FDG in myocardium.
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PET scintigraphy of the heart and 18FDG. This drug markedly de-
creases oxidative degradation of fat and plasmatic level of fatty
acids in healthy men [10] and increases glucose utilisation [11].
Another mechanism with a similar effect in experiments on ani-
mals is tyloxapol (triton WR 1339), a potent surface detergent but
not suitable for human administration, which induces reduction in
heart lipase activity due to the inhibitory effect of free fatty acids
[12]. The increase of 18FDG accumulation in the heart after acipi-
mox, as well as after insulin clamp, was described in myocardial
PET scintigraphies [13, 14].
As mentioned, all studies regarding myocardial 18FDG accu-
mulation and PET scintigraphy carried out till now have not been
able to inform exactly about actual tissue 18FDG concentration
and therefore this problem remains to be solved experimentally.
Our results showed that both lipid-depressing agents significant-
ly increased the myocardial 18FDG concentration 45 minutes after
intravenous injection. In contrast, the increase of 18FDG concen-
tration in myocardium was slight and insignificant after glucose
with insulin. This experimental finding correlates well with scinti-
graphic results in humans, when the accumulation of 18FDG in
normal or abnormal myocardium did not differ after a small or
great dose of insulin, only the image was better due to the lower
blood background [15]. The combination of acipimox and glu-
cose with insulin did not elevate the myocardial 18FDG concentra-
tion as observed in PET scintigraphy by Schröder et al. [16].
Acipimox and tyloxapol markedly decreased 18FDG con-
centration in non-working skeletal muscle of the rat in contrast to
the myocardium, whereas glucose and insulin increased 18FDG
accumulation. Our finding is quite in agreement with similar behav-
iour of glucose uptake described by Jenkins et al. [17]. They stud-
ied the non-labelled glucose utilisation index in skeletal muscle and
myocardium in rats after administration of long-chain fatty acid ox-
idation blocking methyl palmoxyrate and glucose clamp. As in our
experiments, lipid-depressing agent significantly increased glucose
utilisation in the myocardium and simultaneously it was decreased
The 18FDG accumulation in brain was not significantly influ-
enced by the tested drugs; all drugs decreased slightly its con-
centration (most significantly after acipimox) in comparison with
control animals (Fig. 3).
Discussion
The utilisation of FFA as a main fuel source for intact myocardium
has been known for some years [35]. Usually the glucose me-
tabolism in myocardium is inhibited by fatty acids oxidation. The
shift to glucose metabolism is performed at an important level of
ischaemia and lack of oxygen, or when the blood level of FFA is
too low [6]. Similarly, the preference for glucose uptake begins
when the blood level of fatty acids is too low but simultaneously
blood concentration of glucose and insulin is high [7]. Regarding
the ischaemia, the shift to predominant glucose uptake begins at
a very deep reduction of coronary flow, by more than 75%, as has
been demonstrated by experimental data [8].
18FDG is accumulated by myocardium from the blood like glu-
cose but is not completely metabolised by the glucose cycle [3].
Therefore it does not depict accurately the fate of glucose degra-
dation but the grade of its accumulation expresses the ability of
the working myocardium to accumulate glucose for further utilisa-
tion as an energetic source. PET scanning routinely uses 18FDG
for demonstration of well-perfused and viable myocardium, though
the myocardial tissue prefers fatty acids. As mentioned, glucose
uptake and metabolism of myocardium are inhibited by oxidation
of fatty acids [7], and begin to prevail till deep myocardial ischemia
[8]. The preferred uptake and utilisation of fatty acids must be there-
fore depressed in order to increase the demand for glucose. It
has been described by Fuccella et al. [9] that the nicotinic acid
and, even much more, acipimox markedly inhibits lipolysis and
therefore this drug was originally recommended for treatment of
hyperlipidemia. Further, acipimox became the centre of attention
for its depressive effect on lipid metabolism in connection with
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Figure 2. Accumulation of 18FDG in skeletal muscle. Figure 3. The 18FDG accumulation in brain.
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in red skeletal muscle. These results are in accordance with the
fact that the energetic metabolism of myocardium and skeletal
muscle substantially differs. This finding is corroborated by results
of a clinical PET study, published by Nuutila et al. [18]; they ob-
served significantly lower 18FDG accumulation in the heart of en-
durance athletes and increased uptake in femoral muscle.
18FDG concentration in the brain was not markedly influenced
either by acipimox and tyloxapol, or glucose with insulin. Clearly
brain metabolism is not based on free fatty acids; also insulin
does not increase glucose transport through blood-brain barrier,
as was demonstrated under normal circumstances by PET scin-
tigraphy on healthy volunteers [19].
In order to achieve maximal 18FDG accumulation for PET scin-
tigraphy of the heart, it seems to be rather contradictory from the
physiological point of view to feed the myocardium with glucose
and insulin before 18FDG administration, because myocardial
muscle prefers fatty acids as a fuel. Therefore it is more reason-
able to reduce lipid metabolism of the myocardium by lipid de-
pressing agent such as acipimox and to shift substantially myo-
cardial metabolism to glucose utilisation and in this way to aug-
ment simultaneously 18FDG accumulation in the heart.
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